No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 2,188,179 | 2,738,813 | 2,612,464 | 2,822,745 | 2,907,675 | 3,008,803 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 96,412 | 204,183 | 88,382 | 165,413 | 104,947 | 58,379 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Aneka Gas Industri Tbk, an Indonesian enterprise, specializes in the production, distribution, and sale of a diverse array of industrial gases. Its extensive product line includes common atmospheric gases like oxygen, nitrogen, and argon. The company also supplies a range of specialized and mixed gas formulations, such as sulfur hexafluoride, high-purity gases, sterilization agents, compressed natural gas, environmental calibration mixtures, and gases tailored for exhaust emissions engine analysis. Synthetic gases like hydrogen, carbon monoxide, and sulfur dioxide are also part of its offerings. For the healthcare sector, the company provides medical oxygen, nitrous oxide, medical air, nitrogen, carbon dioxide, helium, lung function testing mixtures, blood analysis calibration gases, and cryopreservation gases. Furthermore, hydrocarbon gases including propane, natural gas, liquefied petroleum gas (LPG), and acetylene are available. Additional products encompass ammonia, proprietary Samator fuel gas, and rare atmospheric gases such as krypton, neon, and xenon. Beyond gases, the company offers a suite of related products and services, including medical equipment and supplies, advanced medical gas monitoring systems, on-site gas generation solutions, gas handling and cutting tools, and modular operating theater components. Comprehensive installation services are also provided. Operations are supported by a network of approximately 100 gas filling stations. Established in 1916, this venerable enterprise maintains its headquarters in Jakarta Selatan, Indonesia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Samator Indo Gas Tbk (AGII.JK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
PT Aneka Gas Industri Tbk, an Indonesian enterprise, specializes in the production, distribution, and sale of a diverse array of industrial gases. Its extensive product line includes common atmospheric gases like oxygen, nitrogen, and argon. The company also supplies a range of specialized and mixed gas formulations, such as sulfur hexafluoride, high-purity gases, sterilization agents, compressed natural gas, environmental calibration mixtures, and gases tailored for exhaust emissions engine analysis. Synthetic gases like hydrogen, carbon monoxide, and sulfur dioxide are also part of its offerings. For the healthcare sector, the company provides medical oxygen, nitrous oxide, medical air, nitrogen, carbon dioxide, helium, lung function testing mixtures, blood analysis calibration gases, and cryopreservation gases. Furthermore, hydrocarbon gases including propane, natural gas, liquefied petroleum gas (LPG), and acetylene are available. Additional products encompass ammonia, proprietary Samator fuel gas, and rare atmospheric gases such as krypton, neon, and xenon. Beyond gases, the company offers a suite of related products and services, including medical equipment and supplies, advanced medical gas monitoring systems, on-site gas generation solutions, gas handling and cutting tools, and modular operating theater components. Comprehensive installation services are also provided. Operations are supported by a network of approximately 100 gas filling stations. Established in 1916, this venerable enterprise maintains its headquarters in Jakarta Selatan, Indonesia.